Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by a heterogeneous clinical response to the different treatments. Some patients are difficult to treat and do not reach the treatment targets as clinical remission or low disease activity. Known negative prognostic factors, such as the presence of auto-antiantibodies and joint erosion, the presence of a genetic profile, comorbidities and extra-articular manifestations, pregnancy or a pregnancy wish may concur to the treatment failure. In this review we aimed at identify difficult to treat RA patients and define the optimal therapeutic and environmental targets. Genetic markers of severity such as HLA-DRB1, TRAF1, PSORS1C1 and microRNA 146a are differently associated with joint damage; other gene polymorphisms seem to be associated with response to biologic disease modifying anti-rheumatic drugs (bDMARDs). The presence of comorbidities and/or extra-articular manifestations may influence the therapeutic choice; overweight and obese patients are less responsive to TNF inhibitors. In this context the patient profiling can improve the clinical outcome. Targeting different pathways, molecules, and cells involved in the pathogenesis of RA may in part justify the lack response of some patients. An overview of the future therapeutic targets, including bDMARDs (inhibitors of IL-6, GM-CSF, matrix metalloproteinases, chemokines) and targeted synthetic DMARDs (filgotinib, ABT-494, pefacitinib, decernotinib), and environmental targets is addressed. Environmental factors, such as diet and cigarette smoke, may influence susceptibility to autoimmune diseases and interfere with inflammatory pathways. Mediterranean diet, low salt intake, cocoa, curcumin, and physical activity seem to show beneficial effects, however studies of dose finding, safety and efficacy in RA need to be performed.

Conigliaro, P., Triggianese, P., De Martino, E., Fonti, G.l., Chimenti, M.s., Sunzini, F., et al. (2019). Challenges in the treatment of Rheumatoid Arthritis. AUTOIMMUNITY REVIEWS, 18(7), 706-713 [10.1016/j.autrev.2019.05.007].

Challenges in the treatment of Rheumatoid Arthritis

Conigliaro P.;Triggianese P.;Chimenti M. S.;Perricone R.
2019-01-01

Abstract

Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by a heterogeneous clinical response to the different treatments. Some patients are difficult to treat and do not reach the treatment targets as clinical remission or low disease activity. Known negative prognostic factors, such as the presence of auto-antiantibodies and joint erosion, the presence of a genetic profile, comorbidities and extra-articular manifestations, pregnancy or a pregnancy wish may concur to the treatment failure. In this review we aimed at identify difficult to treat RA patients and define the optimal therapeutic and environmental targets. Genetic markers of severity such as HLA-DRB1, TRAF1, PSORS1C1 and microRNA 146a are differently associated with joint damage; other gene polymorphisms seem to be associated with response to biologic disease modifying anti-rheumatic drugs (bDMARDs). The presence of comorbidities and/or extra-articular manifestations may influence the therapeutic choice; overweight and obese patients are less responsive to TNF inhibitors. In this context the patient profiling can improve the clinical outcome. Targeting different pathways, molecules, and cells involved in the pathogenesis of RA may in part justify the lack response of some patients. An overview of the future therapeutic targets, including bDMARDs (inhibitors of IL-6, GM-CSF, matrix metalloproteinases, chemokines) and targeted synthetic DMARDs (filgotinib, ABT-494, pefacitinib, decernotinib), and environmental targets is addressed. Environmental factors, such as diet and cigarette smoke, may influence susceptibility to autoimmune diseases and interfere with inflammatory pathways. Mediterranean diet, low salt intake, cocoa, curcumin, and physical activity seem to show beneficial effects, however studies of dose finding, safety and efficacy in RA need to be performed.
2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/01
English
Comorbidities; Diet; Extra-articular manifestations; HLA; Physical activity; Pregnancy; Rheumatoid Arthritis; bDMARDs; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans
Conigliaro, P., Triggianese, P., De Martino, E., Fonti, G.l., Chimenti, M.s., Sunzini, F., et al. (2019). Challenges in the treatment of Rheumatoid Arthritis. AUTOIMMUNITY REVIEWS, 18(7), 706-713 [10.1016/j.autrev.2019.05.007].
Conigliaro, P; Triggianese, P; De Martino, E; Fonti, Gl; Chimenti, Ms; Sunzini, F; Viola, A; Canofari, C; Perricone, R
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
2019_Conigliaro Challenges.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 413.39 kB
Formato Adobe PDF
413.39 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/225718
Citazioni
  • ???jsp.display-item.citation.pmc??? 58
  • Scopus 127
  • ???jsp.display-item.citation.isi??? 118
social impact